Skip to main content

Table 2 Heart failure outcome trials completed in 2021: comparison of active vs. placebo group

From: Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

EMPEROR-preserved [37]

Class and cardiovascular outcomes

HR (95% CI)

p-value

Primary composite outcome

 Composite of cardiovascular death or hospitalization for heart failure

0.79 (0.69–0.90)

< 0.001

Secondary outcome

 Total number of hospitalizations for heart failure

0.73 (0.61–0.88)

< 0.001

Secondary outcome

 Mean slope of change in eGFR per year—ml/min/1.73 m2

1.36 (1.06–1.66)

< 0.001

Other prespecified analyses

 Change in KCCQ clinical summary score at week 52

1.32 (0.45–2.19)

 

Other prespecified analyses

 Total number of hospitalizations for any cause

0.93 (0.85–1.01)

 

Other prespecified analyses

 Composite renal outcome

0.95 (0.73–1.24)

 

Other prespecified analyses

 Onset of new diabetes in patients with prediabetes

0.84 (0.65–1.07)

 

Other prespecified analyses

 Death from any cause

1.00 (0.87–1.15)

 

Adverse events

Event rate (%) active vs. placebo group

 

Urinary tract infections

9.9 vs. 8.1

 

Genital infections

2.2 vs. 0.7

 

Hypotension

10.4 vs. 8.6

 
  1. KCCQ Kansas City Cardiomyopathy Questionnaire